Sana Biotechnology is a clinical-stage company developing engineered cells as medicines, with platforms aimed at enabling scalable, off-the-shelf cell therapies and in vivo gene delivery. Its science centers on modifying cells—including immune and stem cells—to treat serious diseases such as cancer, autoimmune conditions and certain genetic or metabolic disorders. Programs combine gene editing, hypoimmune designs and delivery technologies intended to reduce immune rejection and manufacturing constraints. The company is pre-commercial, with value tied to research and development progress rather than product sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -49.4 | — |
| Q2 2025 | 0 | — | -93.8 | — |
| Q3 2025 | 0 | — | -42.1 | — |
| Q4 2025 | 0 | — | -58.8 | — |
| Q1 2026 | 0 | — | -47.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Rezolve AI PLC (RZLV), Elevra Lithium Limited (ELVR), Univest Financial Corporation (UVSP), Willis Lease Finance Corporation (WLFC), STAAR Surgical Company (STAA), Braiin Limited (BRAI)